Skip to main content
    E

    Editas Medicine Inc (EDIT)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $2.44
    +0.17 (+7.49%)

    Market Cap: $375.50M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    56%(22/39)
    Avg Surprise
    -30.14%
    Streak
    1 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.21
    Range$-0.25 - $-0.19
    7 analysts
    EPS Revisions
    6
    0
    7d
    6
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.27+24.1%
    60d ago$-0.28+26.1%
    30d ago$-0.28+26.1%
    7d ago$-0.28+26.4%
    Current$-0.21
    Revenue Consensus
    $5M
    Range$500000 - $12M
    12 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.10
    Range$-0.26 - $0.07
    7 analysts
    Revenue Consensus
    $13M
    Range$3M - $26M
    12 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.10---
    Sep 26EST
    		-$-0.21---
    Jun 26
    Reported Aug 5
    		$-0.15$-0.30+50.00%Beat+53.1%
    Mar 26
    Reported May 5
    		$-0.26$-0.24-8.33%Miss+71.7%
    Dec 25
    Reported Mar 9
    		$-0.06N/A+73.94%Beat+89.1%
    Sep 25
    Reported Nov 10
    		$-0.28$-0.38+26.32%Beat+62.7%
    Jun 25
    Reported Aug 12
    		$-0.32$-0.38+15.79%Beat+61.0%
    Mar 25
    Reported May 12
    		$-0.92$-0.59-55.93%Miss-21.1%
    Dec 24
    Reported Mar 5
    		$-0.55$-0.33-67.38%Miss-139.1%
    Sep 24
    Reported Nov 4
    		$-0.75$-0.77+2.60%Beat-36.4%
    Jun 24
    Reported Aug 7
    		$-0.82$-0.71-15.49%Miss-46.4%
    Mar 24
    Reported May 8
    		$-0.76$-0.64-18.75%Miss-7.0%
    Dec 23
    Reported Feb 28
    		$-0.23N/A+57.41%Beat+73.9%
    Sep 23
    Reported Nov 3
    		$-0.55$-0.58+5.17%Beat+32.1%
    Jun 23
    Reported Aug 2
    		$-0.56$-0.77+27.27%Beat+28.2%
    Mar 23
    Reported May 5
    		$-0.71$-0.78+8.97%Beat+4.1%
    Dec 22
    Reported Feb 22
    		$-0.88$-0.81-8.64%Miss-44.3%
    Sep 22
    Reported Nov 2
    		$-0.81$-0.85+4.71%Beat-42.1%
    Jun 22
    Reported Aug 3
    		$-0.78$-0.80+2.50%Beat+3.7%
    Mar 22
    Reported May 4
    		$-0.74$-0.79+6.33%Beat+14.0%
    Dec 21
    Reported Feb 24
    		$-0.61$-0.72+15.28%Beat+39.0%
    Sep 21
    Reported Nov 8
    		$-0.57$-0.81+29.63%Beat-575.0%
    Jun 21
    Reported Aug 4
    		$-0.81$-0.81+0.00%Beat-88.4%
    Mar 21
    Reported May 5
    		$-0.86$-0.71-21.13%Miss-24.6%
    Dec 20
    Reported Feb 25
    		$-1.00$-0.74-35.14%Miss-35.1%
    Sep 20
    Reported Nov 5
    		$0.12N/A+119.05%Beat+118.2%
    Jun 20
    Reported Aug 6
    		$-0.43$-0.82+47.56%Beat+37.7%
    Mar 20
    Reported May 7
    		$-0.69$-0.79+12.66%Beat-15.0%
    Dec 19
    Reported Feb 26
    		$-0.74$0.06-1333.33%Miss-42.3%
    Sep 19
    Reported Nov 12
    		$-0.66$-0.73+9.59%Beat-106.3%
    Jun 19
    Reported Aug 6
    		$-0.69$-0.62-11.29%Miss+15.9%
    Mar 19
    Reported May 7
    		$-0.60$-0.64+6.25%Beat+10.4%
    Dec 18
    Reported Feb 28
    		$-0.52$-0.32-62.50%Miss+38.1%
    Sep 18
    Reported Nov 7
    		$-0.32N/A+60.49%Beat+50.0%
    Jun 18
    Reported Aug 6
    		$-0.82$-0.66-24.24%Miss-26.2%
    Mar 18
    Reported May 3
    		$-0.67$-0.80+16.25%Beat+21.2%
    Dec 17
    Reported Mar 6
    		$-0.84$-0.78-7.69%Miss+23.6%
    Sep 17
    Reported Nov 7
    		$-0.64$-0.63-1.59%Miss-
    Jun 17
    Reported Aug 9
    		$-0.65$-0.57-14.04%Miss-
    Mar 17
    Reported May 15
    		$-0.85$-0.77-10.39%Miss-
    Dec 16
    Reported Mar 7
    		$-1.10$-0.62-77.42%Miss-

    Key Metrics

    Valuation
    P/E Ratio-3.25EV/EBITDAN/A
    Price/FCF-2.41xFCF Yield-41.41%
    Profitability
    Profit Margin-157.30%Operating Margin-167.30%
    ROE-118.80%ROIC-37.27%
    Financial Health
    Debt/Equity0.53xInterest Coverage-18.67x
    Current Ratio3.19xQuick Ratio3.19x
    Trading Statistics
    Beta2.00Avg Volume3.35M
    52-Week High$4.2852-Week Low$1.66

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$2.65
    SMA 20$2.66
    SMA 50$2.83
    SMA 200$2.65
    EMA 10$2.58
    EMA 20$2.66
    EMA 50$2.76
    EMA 200$2.72

    MACD

    Line: -0.08Signal: -0.06Hist: -0.02

    ADX

    ADX: 20.8+DI: 19.9-DI: 24.5

    Aroon & PSAR

    Aroon Up36.0
    Aroon Down96.0
    PSAR$2.93

    Bollinger Bands

    Upper Band$3.00
    Lower Band$2.32
    %B Position2547%(Upper)
    Band Width0.18

    RSI (14-Day)

    Neutral
    41.8

    Momentum Oscillators

    Stoch %K11.6
    Stoch %D22.9
    Williams %R-73.1
    ROC (10d)-3.2%
    Momentum-0.08
    CCI (20d)-144.9
    MFI (14d)65.4

    Volatility Measures

    ATR (14d)$0.21(8.5%)
    StdDev (20d)0.17
    Hist Vol80.8%(High)

    Volume Flow

    VWAP$2.38
    OBV83.7M
    AD Line-51.0M
    CMF (20d)-0.232

    Volume Metrics

    Avg Vol (20d)3.4M
    Vol Ratio0.5x
    VWMA (20d)$2.68

    Pivot Points

    R3$2.65
    R2$2.56
    R1$2.42
    Pivot Point$2.33
    S1$2.19
    S2$2.10
    S3$1.96

    Advanced Oscillators

    TSI-11.64
    Ultimate Osc41.6
    KST-79.80

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$11.89M$0$29.40M$7.54M$3.58M$0$-1,135,000$0$0$1.14M$60.05M$5.34M
    Cost of Revenue$0$0$805,000$0$0$0$48.61M$0$0$0$1.47M$0
    Gross Profit$11.89M$0$29.40M$7.54M$3.58M$0$-1,135,000$0$0$1.14M$60.05M$5.34M
    Operating Expenses$30.44M$25.00M$37.15M$32.09M$55.12M$76.16M$45.46M$65.67M$71.90M$68.13M$84.01M$55.50M
    R&D$20.18M$14.77M$32.06M$19.77M$16.18M$21.93M$16.87M$47.58M$53.70M$48.79M$69.56M$40.51M
    SG&A$11.60M$10.23M$11.35M$12.32M$12.86M$13.38M$16.35M$18.09M$18.21M$19.34M$14.46M$14.99M
    Operating Income$-18,554,000$-25,003,000$-7,755,000$-24,548,000$-51,544,000$-76,163,000$-46,592,000$-65,666,000$-71,903,000$-66,991,000$-23,963,000$-50,163,000
    Interest Income$1.37M$1.21M$1.68M$1.83M$2.09M$2.72M$3.39M$3.53M$4.30M$5.04M$5.10M$5.14M
    Interest Expense$1.06M$1.07M$-464,000$2.40M$2.02M$2.22M$2.19M$0$0$0$0$0
    Income Before Tax$-18,230,000$-24,982,000$-5,620,000$-25,117,000$-53,235,000$-76,088,000$-45,395,000$-62,141,000$-67,607,000$-61,950,000$-18,874,000$-45,019,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-18,230,000$-24,982,000$-5,620,000$-25,117,000$-53,235,000$-76,088,000$-45,395,000$-62,141,000$-67,607,000$-61,950,000$-18,874,000$-45,019,000
    EBITDA$-18,263,000$-24,633,000$-6,955,000$-23,890,000$-51,725,000$-75,254,000$-45,214,000$-65,398,000$-72,364,000$-67,292,000$-24,613,000$-49,896,000
    EBIT$-18,537,000$-25,116,000$-7,760,000$-24,549,000$-53,302,000$-76,588,000$-46,595,000$-65,671,000$-71,904,000$-66,985,000$-23,976,000$-50,163,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about EDIT

    News

    Editas Medicine stock has November 9, 2026 earnings date

    Editas Medicine (EDIT) is scheduled to report its next earnings on November 9, 2026. The company's second-quarter revenue reached USD 11.89 million, significantly up from USD 2.83 million in the first quarter...

    ad-hoc-news.de•10/15/26•Neutral

    A delivery method generated engineered immune cells inside the body and depleted B cells.

    Editas Medicine (EDIT) is set to present two posters at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress in Hamburg, Germany, on October 28...

    Stock Titan•10/15/26•Neutral

    Editas Medicine to present gene editing research at ESGCT congress

    Editas Medicine announced it will present two posters at the European Society of Gene and Cell Therapy 33rd Annual Congress in October 2026...

    Investing.com•10/14/26•Somewhat-Bullish

    Editas Medicine to present gene editing research at ESGCT congress By Investing.com

    Editas Medicine (NASDAQ:EDIT) announced it will present two posters at the European Society of Gene and Cell Therapy 33rd Annual Congress in October 2026. The presentations will detail research on targeted lipid...

    Investing.com India•10/14/26•Somewhat-Bullish

    Editas Medicine Announces Poster Presentations at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress and Participation in Upcoming Investor Conference

    Editas Medicine announced it will present two posters at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress from October 27-30, 2026, in Hamburg, Germany...

    GlobeNewswire•10/14/26•Somewhat-Bullish

    EDIT Valuation and Fair Value

    P/E
    -3.3x
    P/FCF
    -2.4x
    PEG
    0.0x
    P/B
    2.8x
    See GNG's fair value

    EDIT Profitability: Margins, ROIC and FCF

    Operating margin
    -167.3%
    Net margin
    -157.3%
    ROIC
    -37.3%
    ROE
    -118.8%
    FCF margin
    -246.9%
    FCF yield
    -41.4%

    EDIT Competitors

    CompanyTicker
    Carlsmed, Inc.CARL
    Simulations Plus IncSLP
    Strata Critical Medical, Inc.SRTA
    Orthofix Medical IncOFIX
    I-MabIMAB
    Viemed Healthcare IncVMD
    TruBridge Inc.TBRG
    Wellgistics Health, Inc. Common StockWGRX

    Sector: Healthcare

    EDIT Analyst Ratings

    Consensus
    Hold
    Analysts
    13
    Strong Buy
    0
    Buy
    8
    Hold
    3
    Sell
    0
    Strong Sell
    2

    EDIT Bull Case vs Bear Case

    Bull case

    • EDIT grew quarterly revenue 232.3% year over year.
    • 61.5% of EDIT's analyst ratings are Buy or Strong Buy.

    Bear case

    • EDIT has a -157.3% net profit margin.

    EDIT Earnings: Beat Rate and Next Report

    Beat rate
    5 of 8 quarters (62.5%)
    Average surprise
    4.6%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.21
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    6 up, 0 down

    Frequently Asked Questions About EDIT

    Does EDIT pay dividends?

    Editas Medicine Inc (EDIT) does not currently pay a regular dividend.

    What is EDIT's market cap?

    Editas Medicine Inc (EDIT) has a market capitalization of $375.50M with a current stock price of $2.44.

    Related stocks

    Sector: Healthcare

    All stocks starting with E

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In